Observational studyRespiratory research & clinical practice2026

First-line pembrolizumab for advanced and metastatic non-small cell lung cancer with a PD-L1 TPS ≥ 50% at a Portuguese centre.

Maria João Cavaco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.